<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561925</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1486</org_study_id>
    <secondary_id>2007-003654-29</secondary_id>
    <nct_id>NCT00561925</nct_id>
  </id_info>
  <brief_title>VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients</brief_title>
  <official_title>A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada® in Antiretroviral Therapy naïve HIV-1 Infected Patients (VERxVE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine
      extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR)
      in ARV therapy naïve HIV-1 infected patients after 48 weeks of treatment. Secondary
      objectives are to evaluate safety and pharmacokinetics of NVP XR and NVP IR.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Proportion of Virologic Response at Week 48 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population</measure>
    <time_frame>week 48</time_frame>
    <description>Primary endpoint was the number of patients with a sustained virologic response through week 48 using LLOQ = 50 copies/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimates of the Proportions of Patients Without Loss of Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population</measure>
    <time_frame>week 0 to 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Sustained Virologic Response at Week 144 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population</measure>
    <time_frame>week 144</time_frame>
    <description>Endpoint was the number of patients with a sustained virologic response through week 144 using LLOQ = 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimates for Time to New AIDS or AIDS-related Progression Event or Death, Full Analysis Set Population</measure>
    <time_frame>week 0 to 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of HIV-1 Viral Load (log10 Copies/mL) Change From Baseline at Week 144, Full Analysis Set Population</measure>
    <time_frame>baseline, week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of CD4+ Cell Count (Cells/Cubic Millimeter) Change From Baseline at Week 144, Full Analysis Set Population</measure>
    <time_frame>baseline, week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Rashes</measure>
    <time_frame>until last patient completed 144 weeks (up to 193 weeks)</time_frame>
    <description>Frequency of patients with drug related rash events by functional grouping</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Elevations in Laboratory Measurement by DAIDS Grade</measure>
    <time_frame>until last patient completed 144 weeks (up to 193 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan -Meier Estimate of Cumulative Probability of Permanent Discontinuation of Study Medication</measure>
    <time_frame>week 0 to 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 ALT/AST Abnormalities</measure>
    <time_frame>week 0 to 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 Asymptotic Transaminases Abnormalities</measure>
    <time_frame>week 0 to 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan -Meier Estimate of Cumulative Probability of Clinical Hepatic Events</measure>
    <time_frame>week 0 to 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan -Meier Estimate of Cumulative Probability of Group III or IV Drug-related Rash</measure>
    <time_frame>week 0 to 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Bioavailability Trough C_pre,ss,1</measure>
    <time_frame>week 132</time_frame>
    <description>Relative bioavailability measured of trough concentrations. Analysis based on adjusted by-treatment geometric means, the adjusted geometric mean ratio of NVP XR : NVP IR and it's 90% confidence interval with p-value and the inter-individual geometric coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Hepatic Events</measure>
    <time_frame>until last patient completed 144 weeks (up to 193 weeks)</time_frame>
    <description>Frequency of patients with hepatitis symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1068</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>nevirapine XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nevirapine IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nevirapine IR</intervention_name>
    <description>200 mg BID</description>
    <arm_group_label>nevirapine IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nevirapine XR</intervention_name>
    <description>400 mg QD</description>
    <arm_group_label>nevirapine XR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Signed informed consent in accordance with Good Clinical Practice and local regulatory
             requirements prior to trial participation

          2. HIV-1 infected males or females &gt;= 18 years of age with positive serology (ELISA)
             confirmed by Western blot

          3. No previous antiretroviral treatment

          4. Males with CD4+ counts &gt;50 - &lt;400 cells/ml or females with CD4+ counts &gt;50-&lt;250
             cells/ml

          5. Adequate renal function defined as a calculated creatinine clearance (CLCr) greater
             than or equal to 50 mL/min according to the Cockcroft-Gault formula as follows:

             Male: (140 - age in years) x (weight in kg) divided by 72 x (serum creatinine in
             mg/dl) = CLCr (mL/min).

             Female: (140 - age in years) x (weight in kg) divided by 72 x (serum creatinine in
             mg/dl) x 0.85 = CLCr (mL/min).

          6. Karnofsky score &gt;70 (see Appendix 10.4)

          7. An HIV-1 viral load of 1,000 copies/mL

          8. Willingness to initiate CD4+ cell count-guided chemoprophylaxis to prevent important
             opportunistic infections as defined in Appendix 10.2

          9. Willingness to abstain from ingesting substances which may alter plasma study drug
             levels by interaction with the cytochrome P450 system (listed in Appendix 10.3) during
             the study.

         10. For centers participating in the PK substudy only: Written informed consent in
             accordance with GCP and local legislation for participation in the PK substudy.
             Refusal to participate in the PK substudy is not an exclusion criterion for
             participation in the trial. Only study centers with previous experience and equipped
             in handling PK samples are eligible for participation in the substudy.

        Exclusion criteria:

          1. Active drug abuse or chronic alcoholism at the investigator's discretion

          2. Active hepatitis B or C disease, defined as HBsAg-positive and HBV-DNA-positive or
             HCV-RNA-positive

          3. Female patients of child-bearing potential who: are pregnant at screening; are breast
             feeding; are planning to become pregnant; are not willing to use a barrier method of
             contraception, or; are not willing to use methods of contraception other than ethinyl
             estradiol containing oral contraceptives Note: During participation in this study,
             females and males have to use barrier methods of contraception in addition or instead
             of ethinyl estradiol containing oral contraceptives.

          4. Laboratory parameters &gt;DAIDS Grade 2

          5. ALT/AST &gt; DAIDS Grade 1

          6. Hypersensitivity to any ingredients of the test products

          7. Previous use of Viramune® (nevirapine) or any other antiretroviral agents (does not
             include use of single dose NVP for the prevention of mother to child transmission)

          8. Resistance to NNRTIs or either one of the components of Truvada® (emtricitabine or
             tenofovir disoproxil fumarate) or lamivudine (3TC) based on HIV-1 genotypic resistance
             testing report obtained at screening

          9. Patients who are receiving other concomitant treatments which are not permitted, as
             described in the prescribing information

         10. Use of investigational medications (any experimental agent other than the study
             regimen) within 30 days before study entry or during the trial

         11. Use of immunomodulatory drugs within 30 days before study entry or during the trial
             (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2)

         12. Patients who have been diagnosed with malignant disease

         13. Patients who in the opinion of the investigator are not candidates for inclusion in
             the study

         14. Patient with Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's
             Sarcoma (KS), and/or any lymphoma

         15. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment
             for at least 12 weeks at screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1100.1486.0040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wilton Manors</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.5401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.5402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.5404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.5407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.5408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.5403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.5409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.5405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.6101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.6102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.6104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Surry Hills</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.6103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Francistown</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.1002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.1004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.1013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.1016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.1005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.1010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.1014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.1011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec (Ste Foy)</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3305B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bondy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3317A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3316A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3316B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3314E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caen cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon Cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3308C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon Cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3301B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3301C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3301D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3301E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3301F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3301G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3301H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3301I Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3303D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3312A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3312B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3309A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3309B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3318A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulon cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3318B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulon cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3318C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulon cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3318D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulon cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3302B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3302C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3310A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Villeneuve St Georges cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4928 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4932 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4922 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4911 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4919 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4916 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4929 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4926 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4930 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4909 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4920 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4925 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4915 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4923 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4910 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4924 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4927 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4912 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4918 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osnabrück</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4913 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ulm/Donau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4914 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3531 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 8</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3532 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Verbania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.5207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.5204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>León</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chorzow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.0033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.7002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.7001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2707 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2712 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2709 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2711 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2701 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edenvale</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2710 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2706 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nelspruit</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.2704 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alcalá de Henares (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3415 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3417 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3414 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3416 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mataro</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.3408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genève</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Chaux-de-Fonds</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1486.4402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plaistow, London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Botswana</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Peru</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <results_first_submitted>December 13, 2011</results_first_submitted>
  <results_first_submitted_qc>December 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2012</results_first_posted>
  <last_update_submitted>March 7, 2014</last_update_submitted>
  <last_update_submitted_qc>March 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NVP IR 200mg QD</title>
          <description>Nevirapine immediate release 200 mg given once daily</description>
        </group>
        <group group_id="P2">
          <title>NVP IR 200mg BID</title>
          <description>Nevirapine immediate release 200 mg given twice daily</description>
        </group>
        <group group_id="P3">
          <title>NVP XR 400mg QD</title>
          <description>Nevirapine extended release 400 mg given once daily</description>
        </group>
        <group group_id="P4">
          <title>NVP XR</title>
        </group>
        <group group_id="P5">
          <title>NVP IR to XR</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>14 Day Lead-In Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1068"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1013"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>In/Exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>144-week Double-blind, Double-dummy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="508"/>
                <participants group_id="P3" count="505"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="358"/>
                <participants group_id="P3" count="378"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="127"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="358"/>
                <participants group_id="P5" count="378"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="315"/>
                <participants group_id="P5" count="328"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Declined entry into extension period</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NVP IR 200mg QD</title>
          <description>Nevirapine immediate release 200 mg tablets given once daily</description>
        </group>
        <group group_id="B2">
          <title>NVP IR 200mg BID</title>
          <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
        </group>
        <group group_id="B3">
          <title>NVP XR 400mg QD</title>
          <description>Nevirapine extended release 400 mg tablets given once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="508"/>
            <count group_id="B3" value="505"/>
            <count group_id="B4" value="1013"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="38.0" spread="9.7"/>
                    <measurement group_id="B3" value="38.3" spread="9.7"/>
                    <measurement group_id="B4" value="38.1" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to &lt; 41 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="299"/>
                    <measurement group_id="B4" value="615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41 to &lt; 56 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="182"/>
                    <measurement group_id="B4" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>56 to &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 years or more</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="433"/>
                    <measurement group_id="B3" value="431"/>
                    <measurement group_id="B4" value="864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian / Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian / Pacific Isle.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="376"/>
                    <measurement group_id="B3" value="387"/>
                    <measurement group_id="B4" value="763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic / Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic / Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="399"/>
                    <measurement group_id="B3" value="390"/>
                    <measurement group_id="B4" value="789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America / Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="257"/>
                    <measurement group_id="B4" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="224"/>
                    <measurement group_id="B4" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="168"/>
                    <measurement group_id="B4" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - no interfere with trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="354"/>
                    <measurement group_id="B3" value="335"/>
                    <measurement group_id="B4" value="689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - could interfere with trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Proportion of Virologic Response at Week 48 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population</title>
        <description>Primary endpoint was the number of patients with a sustained virologic response through week 48 using LLOQ = 50 copies/mL</description>
        <time_frame>week 48</time_frame>
        <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR 200mg QD</title>
            <description>Nevirapine immediate release 200 mg tablets given once daily</description>
          </group>
          <group group_id="O2">
            <title>NVP IR 200mg BID</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O3">
            <title>NVP XR 400mg QD</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Proportion of Virologic Response at Week 48 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population</title>
          <description>Primary endpoint was the number of patients with a sustained virologic response through week 48 using LLOQ = 50 copies/mL</description>
          <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="384"/>
                    <measurement group_id="O3" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of nevirapine XR to nevirapine IR was established if the lower bound of the confidence interval was greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran's statistic</method>
            <param_type>Cochran's statistic</param_type>
            <param_value>4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
            <estimate_desc>Weighted treatment difference and corresponding variance were calculated based on Cochran's statistic.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimates of the Proportions of Patients Without Loss of Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population</title>
        <time_frame>week 0 to 144</time_frame>
        <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR 200mg QD</title>
            <description>Nevirapine immediate release 200 mg tablets given once daily</description>
          </group>
          <group group_id="O2">
            <title>NVP IR 200mg BID</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O3">
            <title>NVP XR 400mg QD</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimates of the Proportions of Patients Without Loss of Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population</title>
          <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interval Week 0 to &lt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 2 to &lt;4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.84"/>
                    <measurement group_id="O3" value="0.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 4 to &lt;6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.838"/>
                    <measurement group_id="O3" value="0.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 6 to &lt;8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.834"/>
                    <measurement group_id="O3" value="0.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 8 to &lt;12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.834"/>
                    <measurement group_id="O3" value="0.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 12 to &lt;16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.832"/>
                    <measurement group_id="O3" value="0.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 16 to &lt;24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.83"/>
                    <measurement group_id="O3" value="0.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 24 to &lt;32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.822"/>
                    <measurement group_id="O3" value="0.848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 32 to &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.806"/>
                    <measurement group_id="O3" value="0.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 40 to &lt;48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.792"/>
                    <measurement group_id="O3" value="0.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 48 to &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.777"/>
                    <measurement group_id="O3" value="0.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 60 to &lt;72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.759"/>
                    <measurement group_id="O3" value="0.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 72 to &lt;84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.733"/>
                    <measurement group_id="O3" value="0.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 84 to &lt;96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.713"/>
                    <measurement group_id="O3" value="0.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 96 to &lt;108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.686"/>
                    <measurement group_id="O3" value="0.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 108 to &lt;120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.662"/>
                    <measurement group_id="O3" value="0.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 120 to &lt;132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.65"/>
                    <measurement group_id="O3" value="0.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 132 to &lt;144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.63"/>
                    <measurement group_id="O3" value="0.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 144 to &lt;168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.61"/>
                    <measurement group_id="O3" value="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Sustained Virologic Response at Week 144 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population</title>
        <description>Endpoint was the number of patients with a sustained virologic response through week 144 using LLOQ = 50 copies/mL</description>
        <time_frame>week 144</time_frame>
        <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR 200mg QD</title>
            <description>Nevirapine immediate release 200 mg tablets given once daily</description>
          </group>
          <group group_id="O2">
            <title>NVP IR 200mg BID</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O3">
            <title>NVP XR 400mg QD</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Sustained Virologic Response at Week 144 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population</title>
          <description>Endpoint was the number of patients with a sustained virologic response through week 144 using LLOQ = 50 copies/mL</description>
          <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="296"/>
                    <measurement group_id="O3" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="210"/>
                    <measurement group_id="O3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of nevirapine XR to nevirapine IR was established if the lower bound of the confidence interval was greater than -2%</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran's statistic</method>
            <param_type>Cochran's statistic</param_type>
            <param_value>4.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>10.79</ci_upper_limit>
            <estimate_desc>Weighted treatment difference and corresponding variance were calculated based on Cochran's statistic.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimates for Time to New AIDS or AIDS-related Progression Event or Death, Full Analysis Set Population</title>
        <time_frame>week 0 to 144</time_frame>
        <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR 200mg QD</title>
            <description>Nevirapine immediate release 200 mg tablets given once daily</description>
          </group>
          <group group_id="O2">
            <title>NVP IR 200mg BID</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O3">
            <title>NVP XR 400mg QD</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimates for Time to New AIDS or AIDS-related Progression Event or Death, Full Analysis Set Population</title>
          <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interval Week 0 to &lt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 2 to &lt;4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.006"/>
                    <measurement group_id="O3" value="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 4 to &lt;6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.006"/>
                    <measurement group_id="O3" value="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 6 to &lt;8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.023"/>
                    <measurement group_id="O3" value="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 8 to &lt;12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.029"/>
                    <measurement group_id="O3" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 12 to &lt;16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.029"/>
                    <measurement group_id="O3" value="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 16 to &lt;24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.031"/>
                    <measurement group_id="O3" value="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 24 to &lt;32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.04"/>
                    <measurement group_id="O3" value="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 32 to &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.042"/>
                    <measurement group_id="O3" value="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 40 to &lt;48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.047"/>
                    <measurement group_id="O3" value="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 48 to &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.047"/>
                    <measurement group_id="O3" value="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 60 to &lt;72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.052"/>
                    <measurement group_id="O3" value="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 72 to &lt;84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.054"/>
                    <measurement group_id="O3" value="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 84 to &lt;96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.054"/>
                    <measurement group_id="O3" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 96 to &lt;108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.057"/>
                    <measurement group_id="O3" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 108 to &lt;120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.057"/>
                    <measurement group_id="O3" value="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 120 to &lt;132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.06"/>
                    <measurement group_id="O3" value="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 132 to &lt;144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.06"/>
                    <measurement group_id="O3" value="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 144 to &lt;168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.062"/>
                    <measurement group_id="O3" value="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of HIV-1 Viral Load (log10 Copies/mL) Change From Baseline at Week 144, Full Analysis Set Population</title>
        <time_frame>baseline, week 144</time_frame>
        <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication; descriptive analysis uses the imputation method: last observation carried forward; statistical analysis uses observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR 200mg QD</title>
            <description>Nevirapine immediate release 200 mg tablets given once daily</description>
          </group>
          <group group_id="O2">
            <title>NVP IR 200mg BID</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O3">
            <title>NVP XR 400mg QD</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of HIV-1 Viral Load (log10 Copies/mL) Change From Baseline at Week 144, Full Analysis Set Population</title>
          <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication; descriptive analysis uses the imputation method: last observation carried forward; statistical analysis uses observed cases</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-2.7" spread="0.9"/>
                    <measurement group_id="O3" value="-2.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7719</p_value>
            <method>ANCOVA</method>
            <method_desc>Means adjusted for baseline HIV-1 viral load stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of CD4+ Cell Count (Cells/Cubic Millimeter) Change From Baseline at Week 144, Full Analysis Set Population</title>
        <time_frame>baseline, week 144</time_frame>
        <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication; descriptive analysis uses the imputation method: last observation carried forward; statistical analysis uses observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR 200mg QD</title>
            <description>Nevirapine immediate release 200 mg tablets given once daily</description>
          </group>
          <group group_id="O2">
            <title>NVP IR 200mg BID</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O3">
            <title>NVP XR 400mg QD</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of CD4+ Cell Count (Cells/Cubic Millimeter) Change From Baseline at Week 144, Full Analysis Set Population</title>
          <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication; descriptive analysis uses the imputation method: last observation carried forward; statistical analysis uses observed cases</population>
          <units>cells/cubic millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="239.3" spread="171.4"/>
                    <measurement group_id="O3" value="270.7" spread="183.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0078</p_value>
            <method>ANCOVA</method>
            <method_desc>Means adjusted for baseline HIV-1 viral load stratum</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>32.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.67</ci_lower_limit>
            <ci_upper_limit>57.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Rashes</title>
        <description>Frequency of patients with drug related rash events by functional grouping</description>
        <time_frame>until last patient completed 144 weeks (up to 193 weeks)</time_frame>
        <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR</title>
            <description>Patients received nevirapine IR during the 144 week blinded phase and nevirapine XR during open label extension</description>
          </group>
          <group group_id="O2">
            <title>NVP XR</title>
            <description>Patients receiving nevirapine XR during the 144 week blinded phase and nevirapine XR during open label extension</description>
          </group>
          <group group_id="O3">
            <title>IR-IR/XR</title>
            <description>Patients receiving nevirapine IR during the 144 week blinded phase and then receiving nevirapine XR in the post week 144 of extension</description>
          </group>
          <group group_id="O4">
            <title>XR-IR/XR</title>
            <description>Patients receiving nevirapine XR during open label extension and previously receiving nevirapine IR during the pre week 144</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Rashes</title>
          <description>Frequency of patients with drug related rash events by functional grouping</description>
          <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="505"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rash group I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rash group II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rash group IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rash group III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rash group IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Elevations in Laboratory Measurement by DAIDS Grade</title>
        <time_frame>until last patient completed 144 weeks (up to 193 weeks)</time_frame>
        <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR</title>
            <description>Patients received nevirapine IR during the 144 week blinded phase and nevirapine XR during open label extension</description>
          </group>
          <group group_id="O2">
            <title>NVP XR</title>
            <description>Patients receiving nevirapine XR during the 144 week blinded phase and nevirapine XR during open label extension</description>
          </group>
          <group group_id="O3">
            <title>IR-IR/XR</title>
            <description>Patients receiving nevirapine IR during the 144 week blinded phase and then receiving nevirapine XR in the post week 144 of extension</description>
          </group>
          <group group_id="O4">
            <title>XR-IR/XR</title>
            <description>Patients receiving nevirapine XR during open label extension and previously receiving nevirapine IR during the pre week 144</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Elevations in Laboratory Measurement by DAIDS Grade</title>
          <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="505"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAIDS grade 3 or 4 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAIDS grade 4 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan -Meier Estimate of Cumulative Probability of Permanent Discontinuation of Study Medication</title>
        <time_frame>week 0 to 144</time_frame>
        <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O2">
            <title>NVP XR</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan -Meier Estimate of Cumulative Probability of Permanent Discontinuation of Study Medication</title>
          <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
          <units>cumulative probability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interval Week 0 to &lt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 2 to &lt;4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 4 to &lt;6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034"/>
                    <measurement group_id="O2" value="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 6 to &lt;8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.067"/>
                    <measurement group_id="O2" value="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 8 to &lt;12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.081"/>
                    <measurement group_id="O2" value="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 12 to &lt;16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.093"/>
                    <measurement group_id="O2" value="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 16 to &lt;24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.113"/>
                    <measurement group_id="O2" value="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 24 to &lt;32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.130"/>
                    <measurement group_id="O2" value="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 32 to &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156"/>
                    <measurement group_id="O2" value="0.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 40 to &lt;48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.172"/>
                    <measurement group_id="O2" value="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 48 to &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.192"/>
                    <measurement group_id="O2" value="0.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 60 to &lt;72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.202"/>
                    <measurement group_id="O2" value="0.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 72 to &lt;84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.213"/>
                    <measurement group_id="O2" value="0.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 84 to &lt;96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.229"/>
                    <measurement group_id="O2" value="0.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 96 to &lt;108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.243"/>
                    <measurement group_id="O2" value="0.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 108 to &lt;120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.267"/>
                    <measurement group_id="O2" value="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 120 to &lt;132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.275"/>
                    <measurement group_id="O2" value="0.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 132 to &lt;144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.289"/>
                    <measurement group_id="O2" value="0.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 ALT/AST Abnormalities</title>
        <time_frame>week 0 to 72</time_frame>
        <population>Treated set (TS) includes all patients who were dispensed study medication and were documented to have taken at least one doe of investigational treatment, including the lead in nevirapine dose</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O2">
            <title>NVP XR</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 ALT/AST Abnormalities</title>
          <population>Treated set (TS) includes all patients who were dispensed study medication and were documented to have taken at least one doe of investigational treatment, including the lead in nevirapine dose</population>
          <units>cumulative probability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interval Week 0 to &lt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 2 to &lt;4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 4 to &lt;6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012"/>
                    <measurement group_id="O2" value="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 6 to &lt;8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049"/>
                    <measurement group_id="O2" value="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 8 to &lt;12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.059"/>
                    <measurement group_id="O2" value="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 12 to &lt;16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.063"/>
                    <measurement group_id="O2" value="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 16 to &lt;24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.063"/>
                    <measurement group_id="O2" value="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 24 to &lt;32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.067"/>
                    <measurement group_id="O2" value="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 32 to &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.070"/>
                    <measurement group_id="O2" value="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 40 to &lt;48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076"/>
                    <measurement group_id="O2" value="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 48 to &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076"/>
                    <measurement group_id="O2" value="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 60 to &lt;72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076"/>
                    <measurement group_id="O2" value="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week &gt;=72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076"/>
                    <measurement group_id="O2" value="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 Asymptotic Transaminases Abnormalities</title>
        <time_frame>week 0 to 72</time_frame>
        <population>Treated set (TS) includes all patients who were dispensed study medication and were documented to have taken at least one doe of investigational treatment, including the lead in nevirapine dose</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O2">
            <title>NVP XR</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 Asymptotic Transaminases Abnormalities</title>
          <population>Treated set (TS) includes all patients who were dispensed study medication and were documented to have taken at least one doe of investigational treatment, including the lead in nevirapine dose</population>
          <units>cumulative probability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interval Week 0 to &lt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 2 to &lt;4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 4 to &lt;6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006"/>
                    <measurement group_id="O2" value="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 6 to &lt;8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027"/>
                    <measurement group_id="O2" value="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 8 to &lt;12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033"/>
                    <measurement group_id="O2" value="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 12 to &lt;16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039"/>
                    <measurement group_id="O2" value="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 16 to &lt;24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039"/>
                    <measurement group_id="O2" value="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 24 to &lt;32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.042"/>
                    <measurement group_id="O2" value="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 32 to &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.044"/>
                    <measurement group_id="O2" value="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 40 to &lt;48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053"/>
                    <measurement group_id="O2" value="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 48 to &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053"/>
                    <measurement group_id="O2" value="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 60 to &lt;72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053"/>
                    <measurement group_id="O2" value="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week &gt;=72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053"/>
                    <measurement group_id="O2" value="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan -Meier Estimate of Cumulative Probability of Clinical Hepatic Events</title>
        <time_frame>week 0 to 72</time_frame>
        <population>Treated set (TS) includes all patients who were dispensed study medication and were documented to have taken at least one doe of investigational treatment, including the lead in nevirapine dose</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O2">
            <title>NVP XR</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan -Meier Estimate of Cumulative Probability of Clinical Hepatic Events</title>
          <population>Treated set (TS) includes all patients who were dispensed study medication and were documented to have taken at least one doe of investigational treatment, including the lead in nevirapine dose</population>
          <units>cumulative probability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interval Week 0 to &lt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 2 to &lt;4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 4 to &lt;6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012"/>
                    <measurement group_id="O2" value="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 6 to &lt;8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022"/>
                    <measurement group_id="O2" value="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 8 to &lt;12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024"/>
                    <measurement group_id="O2" value="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 12 to &lt;16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026"/>
                    <measurement group_id="O2" value="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 16 to &lt;24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026"/>
                    <measurement group_id="O2" value="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 24 to &lt;32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026"/>
                    <measurement group_id="O2" value="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 32 to &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026"/>
                    <measurement group_id="O2" value="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 40 to &lt;48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029"/>
                    <measurement group_id="O2" value="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 48 to &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029"/>
                    <measurement group_id="O2" value="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 60 to &lt;72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.032"/>
                    <measurement group_id="O2" value="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week &gt;=72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038"/>
                    <measurement group_id="O2" value="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan -Meier Estimate of Cumulative Probability of Group III or IV Drug-related Rash</title>
        <time_frame>week 0 to 72</time_frame>
        <population>Treated set (TS) includes all patients who were dispensed study medication and were documented to have taken at least one doe of investigational treatment, including the lead in nevirapine dose</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O2">
            <title>NVP XR</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan -Meier Estimate of Cumulative Probability of Group III or IV Drug-related Rash</title>
          <population>Treated set (TS) includes all patients who were dispensed study medication and were documented to have taken at least one doe of investigational treatment, including the lead in nevirapine dose</population>
          <units>cumulative probability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interval Week 0 to &lt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 2 to &lt;4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000"/>
                    <measurement group_id="O2" value="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 4 to &lt;6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002"/>
                    <measurement group_id="O2" value="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 6 to &lt;8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004"/>
                    <measurement group_id="O2" value="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 8 to &lt;12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004"/>
                    <measurement group_id="O2" value="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 12 to &lt;16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004"/>
                    <measurement group_id="O2" value="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 16 to &lt;24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004"/>
                    <measurement group_id="O2" value="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 24 to &lt;32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004"/>
                    <measurement group_id="O2" value="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 32 to &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004"/>
                    <measurement group_id="O2" value="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 40 to &lt;48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004"/>
                    <measurement group_id="O2" value="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 48 to &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004"/>
                    <measurement group_id="O2" value="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week 60 to &lt;72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004"/>
                    <measurement group_id="O2" value="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Week &gt;=72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004"/>
                    <measurement group_id="O2" value="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Bioavailability Trough C_pre,ss,1</title>
        <description>Relative bioavailability measured of trough concentrations. Analysis based on adjusted by-treatment geometric means, the adjusted geometric mean ratio of NVP XR : NVP IR and it's 90% confidence interval with p-value and the inter-individual geometric coefficient of variation.</description>
        <time_frame>week 132</time_frame>
        <population>Only patients with trough drawn PK time window (12+/-2.5 hr for IR; 24+/-5hr for XR) at week 132 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR</title>
            <description>Nevirapine immediate release 200 mg tablets given twice daily</description>
          </group>
          <group group_id="O2">
            <title>NVP XR</title>
            <description>Nevirapine extended release 400 mg tablets given once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Bioavailability Trough C_pre,ss,1</title>
          <description>Relative bioavailability measured of trough concentrations. Analysis based on adjusted by-treatment geometric means, the adjusted geometric mean ratio of NVP XR : NVP IR and it's 90% confidence interval with p-value and the inter-individual geometric coefficient of variation.</description>
          <population>Only patients with trough drawn PK time window (12+/-2.5 hr for IR; 24+/-5hr for XR) at week 132 are included.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4567.03" spread="49.9"/>
                    <measurement group_id="O2" value="3634.26" spread="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>adjusted geometric mean ratio NVP XR : NVP IR</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence test with 80% -125% boundaries</non_inferiority_desc>
            <p_value>0.5542</p_value>
            <p_value_desc>p-value for ratio outside the interval 80%-125%</p_value_desc>
            <method>ANOVA</method>
            <param_type>adjusted gMean</param_type>
            <param_value>79.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.04</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>74.62</ci_lower_limit>
            <ci_upper_limit>84.86</ci_upper_limit>
            <estimate_desc>Inter-individual gCV = 49.9</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Hepatic Events</title>
        <description>Frequency of patients with hepatitis symptoms</description>
        <time_frame>until last patient completed 144 weeks (up to 193 weeks)</time_frame>
        <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
        <group_list>
          <group group_id="O1">
            <title>NVP IR</title>
            <description>Patients received nevirapine IR during the 144 week blinded phase but who never took nevirapine XR during the open label extension</description>
          </group>
          <group group_id="O2">
            <title>NVP XR</title>
            <description>Patients receiving nevirapine XR during the 144 week blinded phase and nevirapine XR during open label extension</description>
          </group>
          <group group_id="O3">
            <title>IR-IR/XR</title>
            <description>Patients receiving nevirapine IR during the 144 week blinded phase and then receiving nevirapine XR in the post week 144 of extension</description>
          </group>
          <group group_id="O4">
            <title>XR-IR/XR</title>
            <description>Patients receiving nevirapine XR during open label extension who had previously received nevirapine IR during the pre week 144</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Hepatic Events</title>
          <description>Frequency of patients with hepatitis symptoms</description>
          <population>Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of blinded medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="505"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 193 weeks</time_frame>
      <desc>Safety data in this report included all the patient visits up to the point in time when the last patient completed 144 weeks in the trial. This also includes safety data for patient visits in the post week 144 open label extension which patients in either treatment group who completed the 144 week blinded phase could enter (see also Limitation).</desc>
      <group_list>
        <group group_id="E1">
          <title>NVP IR 200mg QD</title>
          <description>Nevirapine immediate release 200 mg given once daily</description>
        </group>
        <group group_id="E2">
          <title>NVP IR</title>
          <description>Patients received nevirapine IR during the 144 week blinded phase but who never took nevirapine XR during the open label extension</description>
        </group>
        <group group_id="E3">
          <title>NVP XR</title>
          <description>Patients receiving nevirapine XR during the 144 week blinded phase and nevirapine XR during open label extension</description>
        </group>
        <group group_id="E4">
          <title>NVP IR-IR/XR</title>
          <description>Patients receiving nevirapine IR during the 144 week blinded phase and then receiving nevirapine XR in the post week 144 of extension</description>
        </group>
        <group group_id="E5">
          <title>NVP XR-IR/XR</title>
          <description>Patients receiving nevirapine XR during open label extension who had previously receiving nevirapine IR during the pre week 144</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pericardial rub</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Retroperitoneal fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Polyserositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hepatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AIDS encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Eye infection syphilitic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Meningitis histoplasma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Neurocryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac normal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Plica syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Astrocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bone neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Burkitt's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Epithelioid sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Osteosarcoma localised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Uterine carcinoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cervical root pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Intracranial hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Social phobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Infertility female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Respiratory alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Drug rash with eosinophilia and systemic symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Aborted pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Alcohol use</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Removal of internal fixation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Secondary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="308" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="403" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="271" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="81" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="87" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1068"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="505"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="315"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For the lead-in-period with NVP IR 200mg QD, MedDRA Version 12.1 was used for AE/SAE reporting.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

